MPML yields 2000000.00% · JNJ yields 2.14%● Live data
📍 MPML pulled ahead of the other in Year 1
Combined, MPML + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of MPML + JNJ for your $10,000?
MPM Technologies, Inc., through its subsidiaries, designs, engineers, supplies, and services air pollution control systems for environmental and industrial companies in the United States and internationally. The company provides air pollution control systems by utilizing wet and dry scrubbers, wet electrostatic precipitators, and venturi absorbers that control air pollution. It also involves in the development and commercialization of Skygas, a waste-to-energy process that converts solid and semi-solid wastes into a clean-burning medium BTU gas that can be used for steam production for electric power generation, as well as for downstream conversion into chemicals. The company's Skygas technology is used for the disposal and gasification of carbonaceous wastes, such as municipal solid waste, municipal sewage sludge, pulp and paper mill sludge, auto fluff, medical waste, and used tires. It has a strategic alliance with Foton Technologies, LLC to develop projects to produce power, chemicals, and liquid fuels utilizing Skygas gasification-derived syngas. The company was formerly known as Montana Precision Mining, Ltd. and changed its name to MPM Technologies, Inc. in August 1995. MPM Technologies, Inc. was founded in 1983 and is based in Spokane Valley, Washington. MPM Technologies, Inc. operates as a subsidiary of Carbon Cycle Investments, LLC.
Full MPML Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.